Even more striking, patients with AGS treated with an FDA-approved three-drug NRTI regimen (abacavir, lamivudine, and zidovudine) showed marked reduction in the levels of IFNα proteins and IFN-inducible genes, and an improvement in cerebral blood flow. Here, IFNA1 is linked to Aicardi-Goutieres syndrome.